Advertisement

Topics

Northern Biologics Announces MSC-1 Presentations

13:00 EDT 16 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
--Preclinical data further elucidate potential of LIF inhibition to treat cancer-- Northern Biologics Inc., a developer of first-in-class immuno-oncology products, today announced that its lead asset, MSC-1, is being feature...

Other Sources for this Article

Versant Ventures
Steve Edelson, 415-801-8088
sedelson@versantventures.com

NEXT ARTICLE

More From BioPortfolio on "Northern Biologics Announces MSC-1 Presentations"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...